%0 Journal Article
%A Ossami Saidy, Anna
%A Peczynski, Christophe
%A Thieblemont, Catherine
%A Daskalakis, Michael
%A Wehrli, Marc
%A Beauvais, David
%A Finke, Jürgen
%A Schorb, Elisabeth
%A Vandenberghe, Peter
%A Berning, Philipp
%A Stelljes, Matthias
%A Ayuk, Francis
%A Ram, Ron
%A Von Bonin, Malte
%A Dreger, Peter
%A Bethge, Wolfgang
%A Kuhnl, Andrea
%A Jost, Lasse
%A Stölzel, Friedrich
%A von Tresckow, Bastian
%A Renner, Christoph
%A Fuhrmann, Stephan
%A Galimard, Jacques-Emmanuelle
%A Michel, Eva
%A Bazarbachi, Ali
%A Balari, Anna Sureda
%A Schmitz, Norbert
%A Glass, Bertram
%T Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.
%J HemaSphere
%V 9
%N 5
%@ 2572-9241
%C Hoboken
%I John Wiley & Sons Ltd.
%M DKFZ-2025-01056
%P e70146
%D 2025
%X Patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary central nervous system (CNS) lymphoma (SCNSL) face a dismal prognosis. They have been excluded from most clinical CAR T-cell trials as investigators feared an increased risk for severe immune effector cell-associated neurotoxicity (ICANS). To investigate the potential of anti-CD19 CAR T-cell therapy (CART) in such patients, we analyzed data of 100 patients with CNS manifestation treated with CART between January 2018 and July 2023 and reported to European Society for Blood and Marrow Transplantation. Median age was 62 years. Of patients, 58
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40400509
%2 pmc:PMC12093105
%R 10.1002/hem3.70146
%U https://inrepo02.dkfz.de/record/301519